Page last updated: 2024-11-12

betrixaban

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

betrixaban: a highly potent, selective, and orally efficacious factor Xa inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

betrixaban : A secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10275777
CHEMBL ID512351
CHEBI ID140421
SCHEMBL ID158591
MeSH IDM0538517

Synonyms (52)

Synonym
prt054021
CHEBI:140421 ,
betrixaban
n-(5-chloropyridin-2-yl)-2-[4-(n,n-dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide
prt 054021
bdbm50249298
n-(5-chloropyridin-2-yl)-2-(4-(n,n-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide
AKOS005146070
betrixaban (usan)
330942-05-7
D08873
bevyxxa (tn)
prt-054021
CHEMBL512351 ,
FT-0663094
BCP9000395
n-(5-chloropyridin-2-yl)-2-[[4-(n,n-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
betrixaban [usan:inn]
n-(5-chloropyridin-2-yl)-2-((4-(n,n-dimethylcarbamimidoyl)benzoyl)amino)-5- methoxybenzamide
bevyxxa
benzamide, n-(5-chloro-2-pyridinyl)-2-((4-((dimethylamino)iminomethyl)benzoyl)amino)-5-methoxy-
74rwp7w0j9 ,
unii-74rwp7w0j9
S5388
betrixaban [usan]
betrixaban [who-dd]
betrixaban [mi]
betrixaban [inn]
betrixaban [orange book]
HY-10268
SCHEMBL158591
AC-30214
EX-A358
mfcd16038040
gtpl9602
compound 11 [pmid: 19297154]
NCGC00371122-02
DB12364
Q4898219
BCP01903
AMY11262
SB16951
CCG-269250
NCGC00371122-04
DTXSID10954727
AS-56192
330942-05-7 (free base)
EN300-18167087
compound 11 (pmid: 19297154)
n-(5-chloropyridin-2-yl)-2-((4-(n,n-dimethylcarbamimidoyl)benzoyl)amino)-5-methoxybenzamide
betrixabanum
b01af04

Research Excerpts

Overview

Betrixaban, is an anticoagulant drug approved in 2017 for the prevention of venous thromboembolism. Betrixaban is a FXa inhibitor that decreases prothrombinase activity and thrombin generation.

ExcerptReferenceRelevance
"Betrixaban, is an anticoagulant drug approved in 2017 for the prevention of venous thromboembolism."( Investigation of Poor Solubility of a Salt-Cocrystal Hydrate: A Case Study of the Common-Ion Effect in Betrixaban, an Anticoagulant Drug.
Bollineni, M; Chennuru, R; Devarapalli, R; Indukuri, A; Mondal, A; Reddy, CM, 2021
)
1.56
"Betrixaban is an oral, specific and direct inhibitor of human coagulation factor Xa with demonstrated efficacy and safety for the prevention of VTE in patients undergoing total knee replacement and in patients with nonvalvular atrial fibrillation."( Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Arellano-Rodrigo, E; Díaz-Ricart, M; Escolar, G, 2017
)
2.62
"Betrixaban is a FXa inhibitor that decreases prothrombinase activity and thrombin generation. "( Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
DeRemer, CE; Garland, SG; Gums, JG; Smith, SM, 2018
)
3.37
" Betrixaban is a novel direct oral factor Xa inhibitor approved by the Food and Drug Administration for prophylaxis of venous thromboembolism in adult patients hospitalized for an acute illness at risk for thromboembolic complications. "( Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide.
Chatelain, B; Dogné, JM; Douxfils, J; Evrard, J; Gheldof, D; Mullier, F; Pochet, L; Siriez, R, 2018
)
2.83
"Betrixaban is an oral option for VTE prevention in medical patients."( Overview of betrixaban and its role in clinical practice.
Kalus, JS; Lekura, J, 2018
)
2.3
"Betrixaban is a new NOAC and a factor Xa inhibitor that was approved for extended-duration thromboprophylaxis in these high-risk patients."( Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
Cham, S; Lam, S; Lee, K,
)
2.3
"Betrixaban is an oral direct factor Xa inhibitor recently approved for extended-duration VTE prophylaxis in acute medically ill patients at risk for thromboembolism based on results from the Phase III APEX study."( Betrixaban in the prevention of venous thromboembolism in medically ill patients.
Connors, JM; Sylvester, KW, 2018
)
2.64
"Betrixaban is a novel direct inhibitor of factor Xa with a noteworthy pharmacological feature: limited renal clearance."( The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients.
Babuin, L; Denas, G; Pengo, V; Scarpa, D, 2019
)
1.59
"Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio."( Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
Brenner, MJ; Miller, KM, 2019
)
2.68
"Betrixaban is a novel oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and with low (17%) renal excretion."( Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa).
Connolly, SJ; Dorian, P; Eikelboom, J; Ezekowitz, MD; Gretler, DD; Hohnloser, SH; Sinha, U, 2013
)
2.55
"Betrixaban is a new direct factor Xa inhibitor with distinct pharmacological characteristics, including a long half-life, minimal renal clearance and minimal hepatic metabolism."( Betrixaban (PRT054021): pharmacology, dose selection and clinical studies.
Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J, 2014
)
2.57
"Betrixaban is a new NOAC with distinct pharmacological characteristics: minimal renal clearance, minimal hepatic metabolism, and long half-life."( Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.
Bhagirath, V; Chan, NC; Eikelboom, JW, 2015
)
1.53
"Betrixaban is a fifth DOAC looking to gain marketing approval in the near future, and may have several potentially beneficial properties."( Betrixaban - the next direct factor Xa inhibitor?
Bramlage, K; Bramlage, P; Ferrero, C; Minguet, J; Thoenes, M, 2016
)
2.6

Bioavailability

ExcerptReferenceRelevance
" A class of highly potent, selective, efficacious and orally bioavailable direct factor Xa inhibitors was discovered."( Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
Arfsten, AE; Bao, L; Bauer, SM; Clizbe, LA; Edwards, ST; Fan, J; Goldman, EA; Hollenbach, SJ; Huang, W; Hutchaleelaha, A; Jia, ZJ; Kanter, J; Lambing, JL; Li, W; Pandey, A; Park, G; Probst, GD; Scarborough, RM; Sinha, U; Song, Y; Su, T; Wang, L; Wong, PW; Woolfrey, J; Wu, Y; Zhang, P; Zhu, BY, 2009
)
0.72
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The APEX trial assessed the safety and efficacy of extended-duration thromboprophylaxis using betrixaban. Betrixaban, a new oral direct Xa inhibitor with once-daily dosing and limited renal elimination, significantly reduces the risk of venous thromboembolism.

ExcerptRelevanceReference
" These drugs have predictable pharmacokinetics that allow fixed dosing without laboratory monitoring, and are being compared with vitamin K antagonists or aspirin in phase III clinical trials [corrected]."( New anticoagulants for atrial fibrillation.
Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M, 2009
)
0.35
"The APEX trial assessed the safety and efficacy of extended-duration thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among hospitalized, acutely ill medical patients."( The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Arbetter, DF; Bandman, O; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Korjian, S; Leeds, JM; Lu, SP; Yee, MK, 2017
)
0.92
" Betrixaban, a new oral direct Xa inhibitor with once-daily dosing and limited renal elimination, significantly reduces the risk of venous thromboembolism without increasing the risk for major bleeding."( Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis.
Dobesh, PP; Trevarrow, BJ, 2019
)
2.87
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anticoagulantAn agent that prevents blood clotting.
EC 3.4.21.6 (coagulation factor Xa) inhibitorAn EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of coagulation factor Xa (EC 3.4.21.6).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
benzamides
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
monochloropyridineA chloropyridine in which only one chlorine is attached to the pyridine ring.
monomethoxybenzeneCompounds containing a benzene skeleton substituted with one methoxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency37.90830.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency3.79080.01238.964839.8107AID1645842
Interferon betaHomo sapiens (human)Potency3.79080.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency3.79080.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency3.79080.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency3.79080.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ProthrombinHomo sapiens (human)IC50 (µMol)11.50450.00000.710710.0000AID1198889; AID1459256; AID1585410; AID351700
Coagulation factor XHomo sapiens (human)IC50 (µMol)0.00350.00030.593710.0000AID1459255; AID1585409; AID351693
Coagulation factor XHomo sapiens (human)Ki0.00010.00000.47089.0000AID351693; AID527394
PlasminogenHomo sapiens (human)IC50 (µMol)10.00000.02503.628010.0000AID351704
Tissue-type plasminogen activatorHomo sapiens (human)IC50 (µMol)10.00000.03402.54256.6000AID351702
Vitamin K-dependent protein CHomo sapiens (human)IC50 (µMol)10.00000.03000.68512.6900AID351703
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)8.90000.00091.901410.0000AID351699; AID527423
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki1.80000.00211.840710.0000AID351698
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (128)

Processvia Protein(s)Taxonomy
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
proteolysisPlasminogenHomo sapiens (human)
blood coagulationPlasminogenHomo sapiens (human)
negative regulation of cell population proliferationPlasminogenHomo sapiens (human)
negative regulation of cell-substrate adhesionPlasminogenHomo sapiens (human)
extracellular matrix disassemblyPlasminogenHomo sapiens (human)
tissue regenerationPlasminogenHomo sapiens (human)
fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationPlasminogenHomo sapiens (human)
myoblast differentiationPlasminogenHomo sapiens (human)
muscle cell cellular homeostasisPlasminogenHomo sapiens (human)
tissue remodelingPlasminogenHomo sapiens (human)
biological process involved in interaction with symbiontPlasminogenHomo sapiens (human)
negative regulation of fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of fibrinolysisPlasminogenHomo sapiens (human)
trophoblast giant cell differentiationPlasminogenHomo sapiens (human)
labyrinthine layer blood vessel developmentPlasminogenHomo sapiens (human)
mononuclear cell migrationPlasminogenHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionPlasminogenHomo sapiens (human)
negative regulation of cell-cell adhesion mediated by cadherinPlasminogenHomo sapiens (human)
response to hypoxiaTissue-type plasminogen activatorHomo sapiens (human)
proteolysisTissue-type plasminogen activatorHomo sapiens (human)
blood coagulationTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
protein modification processTissue-type plasminogen activatorHomo sapiens (human)
fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of proteolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
prevention of polyspermyTissue-type plasminogen activatorHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionTissue-type plasminogen activatorHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTissue-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationTissue-type plasminogen activatorHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
proteolysisVitamin K-dependent protein CHomo sapiens (human)
blood coagulationVitamin K-dependent protein CHomo sapiens (human)
negative regulation of blood coagulationVitamin K-dependent protein CHomo sapiens (human)
negative regulation of apoptotic processVitamin K-dependent protein CHomo sapiens (human)
negative regulation of inflammatory responseVitamin K-dependent protein CHomo sapiens (human)
negative regulation of coagulationVitamin K-dependent protein CHomo sapiens (human)
positive regulation of establishment of endothelial barrierVitamin K-dependent protein CHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
protease bindingPlasminogenHomo sapiens (human)
endopeptidase activityPlasminogenHomo sapiens (human)
serine-type endopeptidase activityPlasminogenHomo sapiens (human)
signaling receptor bindingPlasminogenHomo sapiens (human)
protein bindingPlasminogenHomo sapiens (human)
serine-type peptidase activityPlasminogenHomo sapiens (human)
enzyme bindingPlasminogenHomo sapiens (human)
kinase bindingPlasminogenHomo sapiens (human)
protein domain specific bindingPlasminogenHomo sapiens (human)
apolipoprotein bindingPlasminogenHomo sapiens (human)
protein-folding chaperone bindingPlasminogenHomo sapiens (human)
protein antigen bindingPlasminogenHomo sapiens (human)
serine-type endopeptidase activityTissue-type plasminogen activatorHomo sapiens (human)
signaling receptor bindingTissue-type plasminogen activatorHomo sapiens (human)
protein bindingTissue-type plasminogen activatorHomo sapiens (human)
phosphoprotein bindingTissue-type plasminogen activatorHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
serine-type endopeptidase activityVitamin K-dependent protein CHomo sapiens (human)
calcium ion bindingVitamin K-dependent protein CHomo sapiens (human)
protein bindingVitamin K-dependent protein CHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
extracellular regionPlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
plasma membranePlasminogenHomo sapiens (human)
external side of plasma membranePlasminogenHomo sapiens (human)
cell surfacePlasminogenHomo sapiens (human)
platelet alpha granule lumenPlasminogenHomo sapiens (human)
collagen-containing extracellular matrixPlasminogenHomo sapiens (human)
extracellular exosomePlasminogenHomo sapiens (human)
blood microparticlePlasminogenHomo sapiens (human)
Schaffer collateral - CA1 synapsePlasminogenHomo sapiens (human)
glutamatergic synapsePlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
collagen-containing extracellular matrixTissue-type plasminogen activatorHomo sapiens (human)
extracellular regionTissue-type plasminogen activatorHomo sapiens (human)
cytoplasmTissue-type plasminogen activatorHomo sapiens (human)
cell surfaceTissue-type plasminogen activatorHomo sapiens (human)
secretory granuleTissue-type plasminogen activatorHomo sapiens (human)
apical part of cellTissue-type plasminogen activatorHomo sapiens (human)
extracellular exosomeTissue-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexTissue-type plasminogen activatorHomo sapiens (human)
Schaffer collateral - CA1 synapseTissue-type plasminogen activatorHomo sapiens (human)
glutamatergic synapseTissue-type plasminogen activatorHomo sapiens (human)
extracellular spaceTissue-type plasminogen activatorHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionVitamin K-dependent protein CHomo sapiens (human)
endoplasmic reticulumVitamin K-dependent protein CHomo sapiens (human)
endoplasmic reticulum lumenVitamin K-dependent protein CHomo sapiens (human)
Golgi apparatusVitamin K-dependent protein CHomo sapiens (human)
Golgi lumenVitamin K-dependent protein CHomo sapiens (human)
extracellular spaceVitamin K-dependent protein CHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (77)

Assay IDTitleYearJournalArticle
AID351701Inhibition of trypsin2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID351727Oral bioavailability in cynomolgus monkey at 7.5 mg/kg2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1198889Inhibition of human thrombin using acromogenic substrate S-2238 preincubated for 30 mins before substrate addition measured after 20 mins by spectrophotometry2015European journal of medicinal chemistry, May-05, Volume: 95Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation.
AID1585401Anticoagulant activity in citrated rabbit plasma assessed as concentration required to double prothrombin time after 10 mins by coagulometric analysis2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID351697Fraction unbound in human plasma at 10 uM after 30 mins2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1459257Anticoagulant activity in rabbit plasma assessed as increase in prothrombin time after 10 mins by coagulometer2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
AID527407Oral bioavailability in dog2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID1585428Plasma clearance in Sprague-Dawley rat at 1 mg/kg, iv by LC-MS analysis2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID351719Half life in Beagle dog at 0.5 mg/kg, iv and 2.5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID351702Inhibition of tissue plasminogen activator2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1585421Antithrombotic activity in rat model of arteriovenous shunt thrombosis assessed as reduction thrombus weight at 10 mg/kg, po dosed 90 mins before shunt was opened for 15 mins relative to untreated control2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID527410Volume of distribution at steady state in dog2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID1585425Elimination half life in Sprague-Dawley rat at 3 mg/kg, po by LC-MS analysis2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID351699Inhibition of human ERG expressed in HEK293 cells by patch-clamp method2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID527423Inhibition of human ERG by patch clamp assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID1585429Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv by LC-MS analysis2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID527412Oral bioavailability in rat2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID527409Clearance in dog2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID351695Anticoagulant activity in human plasma assessed as concentration required to double the thrombin generation time2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1459261Antithrombotic activity in rat model of arteriovenous shunt assessed as reduction in thrombus weight at 10 mg/kg, po administered 60 mins prior to shunt opening2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
AID527392Volume of distribution at steady state in rat2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID1585405Anticoagulant activity in citrated rabbit plasma assessed as concentration required to double activated partial thromboplastin time after 10 mins by coagulometric analysis2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID351717Oral bioavailability in Beagle dog at 2.5 mg/kg2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1585419Antithrombotic activity in rat model of FeCl3-induced venous thrombosis assessed as reduction thrombus weight at 10 mg/kg, po dosed 60 mins before thrombus formation relative to untreated control2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID351715AUC in rat at 5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID351693Inhibition of Factor 10a2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1459255Inhibition of human factor 10a using substrate S-2765 preincubated for 30 mins followed by substrate addition measured after 20 mins by micro plate reader method2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
AID351700Inhibition of thrombin2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1585408Elimination half life in Sprague-Dawley rat at 1 mg/kg, iv by LC-MS analysis2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID351703Inhibition of activated anticoagulant protein C2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID351709Half life in rat at 1 mg/kg, iv and 5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID351731Clearance in cynomolgus monkey at 0.75 mg/kg, iv and 7.5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1198890Anticoagulant activity in plasma (unknown origin) assessed as concentration required to double the time for fibrin formation2015European journal of medicinal chemistry, May-05, Volume: 95Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation.
AID1585426AUC (0 to infinity) in Sprague-Dawley rat at 3 mg/kg, po by LC-MS analysis2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID1585420Antithrombotic activity in rat model of arteriovenous shunt thrombosis assessed as reduction thrombus weight at 5 mg/kg, po dosed 90 mins before shunt was opened for 15 mins relative to untreated control2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID1585418Antithrombotic activity in rat model of FeCl3-induced venous thrombosis assessed as reduction thrombus weight at 5 mg/kg, po dosed 60 mins before thrombus formation relative to untreated control2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID351713Volume of distribution in rat at 1 mg/kg, iv and 5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID527393Clearance in rat2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID527405Oral bioavailability in monkey2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID351698Binding affinity to human ERG2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID351707Oral bioavailability in rat at 5 mg/kg2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1585422Toxicity in rat assessed as prolongation of tail bleeding dosed orally 60 mins before tails of anesthetized rat were transected and measured over 30 mins2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID351705Inhibition of kallikrein2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1585430Oral bioavailability in Sprague-Dawley rat at 3 mg/kg by LC-MS analysis2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID1585410Inhibition of human recombinant thrombin expressed in HEK293 cells using S-2238 as substrate preincubated for 30 mins followed by substrate addition and measured for 20 mins2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID351721Clearance in Beagle dog at 0.5 mg/kg, iv and 2.5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID351729Half life in cynomolgus monkey at 0.75 mg/kg, iv and 7.5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID351704Inhibition of plasmin2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID527417Clearance in monkey2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID527425Volume of distribution at steady state in monkey2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID351723Volume of distribution in Beagle dog at 0.5 mg/kg, iv and 2.5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1459260Toxicity in po dosed rat assessed as increase in tail bleeding time administered 60 mins prior to tail transection measured over 30 mins2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
AID1585409Inhibition of human factor Xa using S-2222 as substrate preincubated for 30 mins followed by substrate addition and measured for 20 mins2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID1585417Antithrombotic activity in rat model of FeCl3-induced venous thrombosis assessed as reduction thrombus weight at 1 mg/kg, po dosed 60 mins before thrombus formation relative to untreated control2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID1585406Antithrombotic activity in rat model of arteriovenous shunt thrombosis assessed as reduction thrombus weight at 1 mg/kg, po dosed 90 mins before shunt was opened for 15 mins relative to untreated control2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID351735AUC in cynomolgus monkey at 7.5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID527399Anticoagulant activity in human platelet assessed as concentration required to double prothrombin time2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID351733Volume of distribution in cynomolgus monkey at 0.75 mg/kg, iv and 7.5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1459258Anticoagulant activity in rabbit plasma assessed as increase in activated partial thromboplastin time after 10 mins by coagulometer2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
AID1585423Toxicity in rat assessed as prolongation of tail bleeding at 1 to 10 mg/kg, po dosed 60 mins before tails of anesthetized rat were transected and measured over 30 mins2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID1585407Cmax in Sprague-Dawley rat at 3 mg/kg, po by LC-MS analysis2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID527394Inhibition of factor 10a2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID351696Anticoagulant activity in rabbit deep vein thrombosis model plasma assessed as concentration required to double the thrombin generation time2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID351725AUC in Beagle dog at 2.5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1459256Inhibition of human thrombin using substrate S-2238 preincubated for 30 mins followed by substrate addition measured after 20 mins by micro plate reader method2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
AID1585427AUC (0 to infinity) in Sprague-Dawley rat at 1 mg/kg, iv by LC-MS analysis2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID351711Clearance in rat at 1 mg/kg, iv and 5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
AID1585431Cytoprotective activity against hypoxia/reoxygenation-induced toxicity in rat H9c2 cells assessed as increase in cell viability at 1 to 10 uM by MTT assay2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID1585424Tmax in Sprague-Dawley rat at 3 mg/kg, po by LC-MS analysis2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1345896Human coagulation factor X (S1: Chymotrypsin)2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (88)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (2.27)29.6817
2010's69 (78.41)24.3611
2020's17 (19.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.71 (24.57)
Research Supply Index4.74 (2.92)
Research Growth Index5.86 (4.65)
Search Engine Demand Index68.22 (26.88)
Search Engine Supply Index1.96 (0.95)

This Compound (46.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (20.00%)5.53%
Reviews35 (36.84%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (43.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered Andexanet After Dosing to Steady-State With Oral Betrixaban in Healthy Subjects [NCT03330457]Phase 218 participants (Actual)Interventional2015-08-06Terminated(stopped due to Ended prematurely)
A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations [NCT02596100]Phase 152 participants (Actual)Interventional2015-09-30Completed
A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers. [NCT01765868]Phase 18 participants (Actual)Interventional2007-09-30Completed
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients [NCT01583218]Phase 37,513 participants (Actual)Interventional2012-03-31Completed
A Phase 2, Randomized, Parallel Group, Dose-Finding, Multicenter, Multinational Study of the Safety, Tolerability and Pilot Efficacy of Three Blinded Doses of the Oral Factor Xa Inhibitor Betrixaban Compared With Open-Label Dose-Adjusted Warfarin in Patie [NCT00742859]Phase 2508 participants (Actual)Interventional2008-10-31Completed
Evaluation of the Factor Xa Inhibitor, PRT054021, Against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events After Unilateral Total Knee Replacement (EXPERT) [NCT00375609]Phase 2215 participants (Actual)Interventional2006-05-31Completed
AN OPEN-LABEL, SINGLE-DOSE, MASS-BALANCE STUDY TO ASSESS THE DISPOSITION OF 14C-LABELED PRT054021 IN HEALTHY MALE SUBJECTS [NCT01765855]Phase 15 participants (Actual)Interventional2007-09-30Completed
A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Betrixaban in Pediatric Patients [NCT03346083]Phase 121 participants (Actual)Interventional2018-07-18Completed
Pharmacokinetics, Pharmacodynamics, and Tolerability of Betrixaban Administered Orally in Subjects With Normal and Reduced Renal Function. [NCT00999336]Phase 132 participants (Actual)Interventional2009-07-31Completed
A Phase II, Open-label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients With Nonvalvular Atrial Fibrillation or Atrial Flutter [NCT01229254]Phase 2189 participants (Actual)Interventional2010-09-30Completed
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study [NCT04684212]2,931 participants (Anticipated)Interventional2023-12-01Not yet recruiting
The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist [NCT03397888]Phase 132 participants (Actual)Interventional2017-11-16Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00375609 (3) [back to overview]Incidence of Adjudicated Overt Bleeding Events: Primary Safety Endpoint
NCT00375609 (3) [back to overview]Incidence of Adjudicated Pulmonary Embolism (PE) and All Deep Vein Thrombosis (DVT) (Proximal and Distal)
NCT00375609 (3) [back to overview]Incidence of Adjudicated Venous Thromboembolism (VTE)
NCT00742859 (2) [back to overview]Exposure-adjusted Incidence Rate of Any Bleeding (Major, Clinically Relevant Non-major, or Minimal)
NCT00742859 (2) [back to overview]Exposure-adjusted Incidence Rate of Major or Clinically Relevant Non-major Bleeding Episode
NCT00999336 (9) [back to overview]Area Under The Plasma Concentration-Time Curve From Time Zero To 24 Hours (AUC0-24) Postdose Of Oral Doses Of Betrixaban On Day 8
NCT00999336 (9) [back to overview]Maximum Observed Plasma Concentration (Cmax) Following Administration Of Oral Doses Of Betrixaban On Day 8
NCT00999336 (9) [back to overview]Percentage Of Betrixaban Bound To Plasma Proteins On Day 8
NCT00999336 (9) [back to overview]Percentage Of Dose Excreted In Urine From 0-24 (fe0-24) Postdose Of Oral Doses Of Betrixaban On Day 8
NCT00999336 (9) [back to overview]Plasma Terminal Elimination Half-Life (T½) Following Administration Of Oral Doses Of Betrixaban On Day 8
NCT00999336 (9) [back to overview]Total Plasma Clearance (CL/F) Following Administration Of Oral Doses Of Betrixaban On Day 8
NCT00999336 (9) [back to overview]Volume Of Distribution During The Terminal Phase (Vz/F) Following Administration Of Oral Doses Of Betrixaban On Day 8
NCT00999336 (9) [back to overview]Anti-Factor Xa (fXa) Activity Following Administration Of Oral Doses Of Betrixaban On Day 8
NCT00999336 (9) [back to overview]Thrombin Generation Following Administration Of Oral Doses Of Betrixaban On Day 8
NCT01229254 (2) [back to overview]Steady-state C12 hr on Days 14, 18, and 21 After Weight and Amiodarone-based Dosing
NCT01229254 (2) [back to overview]Steady-state C12 hr on Days 14, 18, and 21 After Weight-based Dosing
NCT01583218 (7) [back to overview]mITT Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3
NCT01583218 (7) [back to overview]mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3
NCT01583218 (7) [back to overview]mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3
NCT01583218 (7) [back to overview]mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3
NCT01583218 (7) [back to overview]mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3
NCT01583218 (7) [back to overview]Modified Intent-to-Treat (mITT) Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic Deep Vein Thrombosis (DVT), Non-fatal Pulmonary Emboli (PE), VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3
NCT01583218 (7) [back to overview]Percentage of Participants Experiencing Major Bleeding Through Seven Days After Discontinuation of All Study Medication
NCT03330457 (2) [back to overview]Change in Anti-Fxa Activity From Baseline to End of Bolus
NCT03330457 (2) [back to overview]Change in Thrombin Generation From Baseline to End of Bolus

Incidence of Adjudicated Overt Bleeding Events: Primary Safety Endpoint

The incidence of adjudicated major and clinical relevant non-major bleeding. Major bleeding was defined as fatal, involving vital organs, requiring additional surgery or a new therapeutic procedure, or a bleeding index >=2. Bleeding Index was defined as the number of units of packed red blood cells or whole blood transfused plus the haemoglobin values before the bleeding episode minus the haemoglobin values after the bleed had stabilized (in g/dL) (NCT00375609)
Timeframe: Through follow-up at approximately 6 (±2) weeks after TKR surgery

InterventionPercentage of Participants (Number)
Betrixaban 15 mg0
Betrixaban 40 mg2.4
Enoxaparin7.0

[back to top]

Incidence of Adjudicated Pulmonary Embolism (PE) and All Deep Vein Thrombosis (DVT) (Proximal and Distal)

Incidence of adjudicated pulmonary embolism (PE) and all deep vein thrombosis (DVT) (proximal and distal) through the time of venography on Day 10 to 14 and at follow-up at approximately 6 (±2) weeks after TKR surgery (NCT00375609)
Timeframe: At follow-up at approximately 6 (±2) weeks after TKR surgery

InterventionPercentage of Participants (Number)
Betrixaban 15 mg20
Betrixaban 40 mg15.4
Enoxaparin12.5

[back to top]

Incidence of Adjudicated Venous Thromboembolism (VTE)

Incidence of adjudicated venous thromboembolism (VTE) through Day 10-14 following TKR where VTE is defined as DVT (proximal and/or distal) and/or PE. Patients were evaluated for VTE daily while hospitalized and were contacted every 2 to 4 days after discharge and before the day of the mandatory venogram to monitor for study endpoints (NCT00375609)
Timeframe: Through Day 10-14 following TKR surgery, at time of mandatory venogram

InterventionPercentage of Participants (Number)
Betrixaban 15 mg20
Betrixaban 40 mg15.4
Enoxaparin10

[back to top]

Exposure-adjusted Incidence Rate of Any Bleeding (Major, Clinically Relevant Non-major, or Minimal)

The time to the first occurrence of any bleeding event. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution. (NCT00742859)
Timeframe: A maximum of 1 year

InterventionNumber of Patients per 100 Patient years (Number)
Betrixaban 40 mg50.5
Betrixaban 60 mg77.9
Betrixaban 80 mg56.0
Warfarin103

[back to top]

Exposure-adjusted Incidence Rate of Major or Clinically Relevant Non-major Bleeding Episode

The primary endpoint is the time to the first occurrence of major or clinically relevant non-major bleeding. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution. (NCT00742859)
Timeframe: A maximum of 1 year

InterventionNumber of Patients per 100 Patient years (Number)
Betrixaban 40 mg2.02
Betrixaban 60 mg10.1
Betrixaban 80 mg10.5
Warfarin14.6

[back to top]

Area Under The Plasma Concentration-Time Curve From Time Zero To 24 Hours (AUC0-24) Postdose Of Oral Doses Of Betrixaban On Day 8

"Blood and urine samples for pharmacokinetic analysis were collected and determined from the plasma and urine concentrations of betrixaban using non-compartmental procedures in WinNonlin Enterprise Version 5.2.~Results were reported in nanogram multiplied by hour per milliliter (ng*h/mL)." (NCT00999336)
Timeframe: Predose up to 168 hours postdose

Interventionng*h/mL (Mean)
Normal Renal Function437
Mild Renal Impairment807
Moderate Renal Impairment1033
Severe Renal Impairment995

[back to top]

Maximum Observed Plasma Concentration (Cmax) Following Administration Of Oral Doses Of Betrixaban On Day 8

"Blood and urine samples for pharmacokinetic analysis were collected and determined from the plasma and urine concentrations of betrixaban using non-compartmental procedures in WinNonlin Enterprise Version 5.2.~Results were reported in nanogram per milliliter (ng/mL)." (NCT00999336)
Timeframe: Predose, up to 168 hours postdose

Interventionng/mL (Mean)
Normal Renal Function44.0
Mild Renal Impairment84.3
Moderate Renal Impairment108
Severe Renal Impairment104

[back to top]

Percentage Of Betrixaban Bound To Plasma Proteins On Day 8

Blood samples were collected for measurement of plasma protein binding for betrixaban for all participants. Results of protein binding assays were summarized by sample time and eGFR group. Results were reported in percent (%). (NCT00999336)
Timeframe: 4 hours Postdose at Day 8

Interventionpercentage of bound betrixaban (Mean)
Normal Renal Function58.6
Mild Renal Impairment61.3
Moderate Renal Impairment59.4
Severe Renal Impairment59.9

[back to top]

Percentage Of Dose Excreted In Urine From 0-24 (fe0-24) Postdose Of Oral Doses Of Betrixaban On Day 8

"Blood and urine samples for pharmacokinetic analysis were collected and determined from the plasma and urine concentrations of betrixaban using non-compartmental procedures in WinNonlin Enterprise Version 5.2.~Results were reported in percentage." (NCT00999336)
Timeframe: Predose, up to 24 hours postdose

Interventionpercentage of excreted dose (Mean)
Normal Renal Function5.07
Mild Renal Impairment5.40
Moderate Renal Impairment5.04
Severe Renal Impairment2.72

[back to top]

Plasma Terminal Elimination Half-Life (T½) Following Administration Of Oral Doses Of Betrixaban On Day 8

"Blood and urine samples for pharmacokinetic analysis were collected and determined from the plasma and urine concentrations of betrixaban using non-compartmental procedures in WinNonlin Enterprise Version 5.2.~Harmonic mean and Jackknife standard deviation was used to report this outcome and results were reported in hour." (NCT00999336)
Timeframe: Predose, up to 168 hours postdose

Interventionhour (Mean)
Normal Renal Function54.4
Mild Renal Impairment56.0
Moderate Renal Impairment60.7
Severe Renal Impairment55.6

[back to top]

Total Plasma Clearance (CL/F) Following Administration Of Oral Doses Of Betrixaban On Day 8

"Blood and urine samples for pharmacokinetic analysis were collected and determined from the plasma and urine concentrations of betrixaban using non-compartmental procedures in WinNonlin Enterprise Version 5.2.~Results were reported in milliliter per minute (mL/min)." (NCT00999336)
Timeframe: Predose, up to 168 hours postdose

InterventionmL/min (Mean)
Normal Renal Function4042
Mild Renal Impairment1815
Moderate Renal Impairment1887
Severe Renal Impairment1715

[back to top]

Volume Of Distribution During The Terminal Phase (Vz/F) Following Administration Of Oral Doses Of Betrixaban On Day 8

"Blood and urine samples for pharmacokinetic analysis were collected and determined from the plasma and urine concentrations of betrixaban using non-compartmental procedures in WinNonlin Enterprise Version 5.2.~Results were reported in liter." (NCT00999336)
Timeframe: Predose, up to 168 hours postdose

Interventionliter (Mean)
Normal Renal Function20128
Mild Renal Impairment8795
Moderate Renal Impairment9518
Severe Renal Impairment9562

[back to top]

Anti-Factor Xa (fXa) Activity Following Administration Of Oral Doses Of Betrixaban On Day 8

"Blood samples were collected at the protocol-specified time points. Plasma samples were assayed for measurement of anti-fXa activity at baseline and steady state for all participants.~Results were reported in international units per milliliter (IU/mL)." (NCT00999336)
Timeframe: Day 8: 2, 3, 4, 8, 24, and 48 hours postdose

,,,
InterventionIU/mL (Mean)
Day 8 2 hDay 8 3 hDay 8 4 hDay 8 8 hDay 8 24 hDay 8 48 h
Mild Renal Impairment0.360.400.330.180.130.08
Moderate Renal Impairment0.480.600.580.320.180.13
Normal Renal Function0.180.270.220.100.06NA
Severe Renal Impairment0.440.770.580.300.180.12

[back to top]

Thrombin Generation Following Administration Of Oral Doses Of Betrixaban On Day 8

Blood samples were collected at the protocol-specified time points. Plasma samples were assayed for measurement of thrombin generation for all participants. (NCT00999336)
Timeframe: Day 1: predose; Day 8: 2, 3, 4, 8, 24, and 48 hours postdose

,,,
Interventionrelative fluorescence units (RFU) (Mean)
Day 1 PredoseDay 8 2 hDay 8 3 hDay 8 4 hDay 8 8 hDay 8 24 hDay 8 48 h
Mild Renal Impairment14168448453565103878958708350
Moderate Renal Impairment11833487350986216790773868119
Normal Renal Function124946359661168999716861612233
Severe Renal Impairment10021477355476154748280138485

[back to top]

Steady-state C12 hr on Days 14, 18, and 21 After Weight and Amiodarone-based Dosing

Betrixaban PK concentration at 12 hr on Days 14, 18, and 21 in amiodarone, low and high weight groups (NCT01229254)
Timeframe: Days 14, 18, and 21 of the PK period

Interventionng/mL (Geometric Least Squares Mean)
Betrixaban9.498

[back to top]

Steady-state C12 hr on Days 14, 18, and 21 After Weight-based Dosing

Betrixaban PK concentration at 12 hr on Days 14, 18, and 21 in low and high weight groups (NCT01229254)
Timeframe: Days 14, 18, and 21 of the PK period

Interventionng/mL (Geometric Least Squares Mean)
Betrixaban 60 mg (<80 kg)7.870
Betrixaban 90 mg (≥80 kg)10.517

[back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top]

Percentage of Participants Experiencing Major Bleeding Through Seven Days After Discontinuation of All Study Medication

Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)

InterventionPercentage of Participants (Number)
Betrixaban0.67
Enoxaparin0.57

[back to top]

Change in Anti-Fxa Activity From Baseline to End of Bolus

Change in Anti-Fxa Activity from baseline to end of bolus (NCT03330457)
Timeframe: Baseline to end of bolus, approximately 2.5 hours

Interventionug/L (Mean)
Cohort 1 Bertrixaban/Andexanet-23.45
Cohort 1 Bertrixaban/Placebo-1.67
Cohort 2 Bertrixaban/Andexanet-26.17
Cohort 2 Bertrixaban/Placebo-2.17

[back to top]

Change in Thrombin Generation From Baseline to End of Bolus

Change in Thrombin Generation from baseline to end of bolus (NCT03330457)
Timeframe: Baseline to end of bolus, approximately 2.5 hours

InterventionRFU (Mean)
Cohort 1 Bertrixaban/Andexanet129984.5
Cohort 1 Bertrixaban/Placebo28646.7
Cohort 2 Bertrixaban/Andexanet116834.7
Cohort 2 Bertrixaban/Placebo15998.7

[back to top]